Japanese
English
Home
About Us
Our Mission
Leadership
Message from CEO
Corporate Information
Access
Our Science
PRIME Technology
Application of Our Technology
Pipelines
Our Partners
Careers
Contact Us
Contact Us
Create the Future to Overcome Cancer
News
2023/04/24
Alliance between Noile-Immune Biotech, Inc. and Rebirthel Co., Ltd. on PRIME allogeneic CAR-T Cell Therapy using Immune Cells induced from Pluripotent Stem Cells
2023/04/24
An interview with our president and CEO, Koji Tamada, was published in the International Pharmaceutical Intelligence Magazine (Dec. 26, 2022 published) under the title of "Top Interview: Creating New Therapeutic Options for Solid Cancer with PRIME CAR-T Cell Technologies." (the article is in Japanese)
2023/04/13
Publication of Research Papers on CAR-T Cells with Our Platform-based Technologies
2022/11/25
Interim results of Phase 1 clinical trial evaluating the ‘PRIME' CAR-T cell therapy TAK-102 (NIB102) expressing IL-7/CCL19 in patients with GPC3 positive solid tumors were presented at the 37th Annual Meeting of SITC
2022/09/12
On September 11, 2022, our president, Koji Tamada, appeared on NHK Science Zero, ”Challenge cancer with immune-therapy ! CAR-T Cell Therapy”
Details